Mike Guerra

California Life Sciences is proud to announce our Fall 2024 FAST cohort! These startups have been selected to receive 12 weeks of business mentoring from expert advisors through CLS’ advisory program, FAST California. Learn more about these start-ups: bit.ly/4egKF89

Overriding patent rights will harm #lifesciences innovation. @CLS_CEO Mike Guerra: "This policy creates uncertainty in the innovation ecosystem, risking the loss of new cures and harming small biotechs who face a challenging investment climate." STATEMENT: bit.ly/3Ri4H88

NEW: California Life Sciences President & CEO Mike Guerra's statement on @IAmBiotech's newly appointed CEO John Crowley 👇 Learn more: bit.ly/3R3t9dc

🌟 Save the date for our inaugural Inclusive Leadership Symposium! Join #lifesciences leaders in San Francisco for a day of learning, reflection, and actionable change to embrace inclusion and equity. Register now: bit.ly/3umxSPr #HealthEquity #DEI #WeCommitToChange

OPINION 🗣 Superbugs are estimated to kill up to 10 million people a year by 2050. Today in the @EastBayTimes & @mercnews, @CLS_CEO shares how the PASTEUR Act would revive the American antimicrobial industry, ensuring patient access to treatments: bayareane.ws/3S6Cpzf

CLS congratulates @LaphonzaB on her appointment to the U.S. Senate. We look forward to working with the Senator on behalf of California innovators and patients.

ANNOUNCING The #Pantheon2023 Finalists! 👏 California's leading #lifesciences innovators have been chosen, and now they need YOUR VOTE! Cast your vote by Oct 13: bit.ly/45dOohw

It’s #WestCoastCGT Symposium day! Follow along here as we explore the promise and potential of cell and gene therapies and dig into how our ecosystem can bring solutions to patients more efficiently. @JNJInnovation @JLABS

LAST CHANCE: Join #lifesciences professionals from companies like @genentech, @GladstoneInst, and @Bayer at next week's Cell & Gene Therapy West Coast Symposium! See who's coming and get tickets while you can: bit.ly/3PiAru4 @JNJInnovation

But by the Congressional Budget Offices’ own estimates, this law puts the promise of new therapies out of reach. We encourage the Administration & Congress to change course, promote therapeutic innovation, & protect America’s leading role in global life sciences innovation. (4/4)

...and we're already seeing the Inflation Reduction Act’s harm for entrepreneurs and small biotechs who face declining investment and rising costs. Patients and their loved ones deserve hope. (3/4)

...this harmful policy’s impact will be felt far beyond these therapies and manufacturers–it has repercussions for every researcher, investor, & company regardless of size in the biopharma sector. CLS is proud to represent and advocate for the entire innovation ecosystem... (2/4)

Today’s announcement by the Centers for Medicare and Medicaid Services is another disappointing step in the administration’s price-setting agenda which will irreversibly harm innovation. While CMS has named the first ten drugs subject to a one-sided negotiation... (1/4)

Check out our new 2023 Sector Report! It has some great information in it...

The latest edition of Life Sciences Insights is out now! 🍃♻ This issue explores environmental sustainability. You’ll read about the immense potential our sector holds in combating the challenges posed by climate change. READ: bit.ly/3O9zdkc

📢 We're excited to announce Brent Fisk as our new Senior Vice President of Government Relations and External Affairs. Learn more: bit.ly/43nzC6O

Which California #biotech or #pharmaceutical company made the greatest advancement this year? Let us know by nominating them for the #Pantheon2023 Awards in the BioPharma category. 👇🏽 bit.ly/43elzRb

Nominations are NOW OPEN for our 20th annual Pantheon Awards! Who do you think should be celebrated for #lifesciences excellence? View the award categories and submit your nominations by August 11: bit.ly/4463mWw #Pantheon2023

New from @VitalTransform and @IAmBIOTech: Patients will lose access to 40% of medicines that would have otherwise been developed over the next 10 years because of the IRA’s price controls. Read the full report: bio.org/sites/default/…

Late Friday night, the Supreme Court stayed lower court orders that would have removed patients' & providers' access to mifepristone. CLS is pleased they chose to uphold the FDA's science-driven review and approval process, and we'll remain engaged as the court process continues.